Danish drugmaker Novo Nordisk is partnering with ChatGPT’s parent company, OpenAI, to bring ‘better treatment options’ for patients. The development comes as pharma companies are increasingly relying on AI to boost R&D and operations.
​Danish drugmaker Novo Nordisk is partnering with ChatGPT’s parent company, OpenAI, to bring ‘better treatment options’ for patients. The development comes as pharma companies are increasingly relying on AI to boost R&D and operations. by Soban News (international And National News)
